亞洲知識產權資訊網為知識產權業界提供一個一站式網上交易平台，協助業界發掘知識產權貿易商機，並與環球知識產權業界建立聯繫。無論你是知識產權擁有者正在出售您的知識產權，或是製造商需要購買技術以提高操作效能，又或是知識產權配套服務供應商，你將會從本網站發掘到有用的知識產權貿易資訊。

返回搜索結果

Prokineticin 2 and Prokineticin Receptor 2 as a Target to Treat Epilepsy and Seizures

詳細技術說明: Researchers at the University of California have found that PK2 is an important regulator of seizure onset and epilepsy. A PKR2 modulator would thus help treat epileptic patients and/or patients suffering from non-epileptic seizures. Certain materials such as cDNAs and cell lines that may be used as screening and research tools are readily available for licensing. This technology is also available for sponsor research opportunities.

*Abstract: PK2 belongs to a family of secreted peptides that regulate diverse biological functions including serving as a regulatory molecule for circadian rhythms. The signaling of PK2 is mediated through two cognate G-protein coupled receptors Prokineticin Receptor 1 and Prokineticin Receptor 2 (PKR1 and PKR2).

*Principal Investigation: Name: Michelle Cheng
Department:

Name: Alex Lee
Department:

Name: Robert Sapolsky
Department:

Name: Qun-Yong Zhou
Department:

附加資料: Patent Number: US8101158B1
Application Number: US200825673A
Inventor: Zhou, Qun-Yong | Lee, Alex G. | Cheng, Michelle Y. | Sapolsky, Robert M.
Priority Date: 2 Feb 2007
Priority Number: US8101158B1
Application Date: 4 Feb 2008
Publication Date: 24 Jan 2012
IPC Current: A61K004900 | A61K0031535
US Class: 4240091 | 5142312
Assignee Applicant: The Regents of the University of California
Title: Methods for treating cerebrovascular disease comprising administering an agent that inhibits prokineticin receptor activity
Usefulness: Methods for treating cerebrovascular disease comprising administering an agent that inhibits prokineticin receptor activity
Summary: The method is useful for treating cerebrovascular diseases in a subject, preferably mammal or human, including cerebral ischemia (all claimed), cerebral hemorrhage, ischemic stroke, hemorrhagic stroke, ischemic reperfusion injury, seizure disorders, and epilepsy. Tests details are described but no results given.
Novelty: Treating cerebrovascular disease in subject, comprises administering prokineticin receptor antagonist, where infarct size is reduced as compared to infarct size without administration of the antagonist

欲了解更多信息，請點擊這裡